4.6 Article

New discriminant score to predict the fibrotic stage of non-alcoholic steatohepatitis in Japan

Journal

HEPATOLOGY INTERNATIONAL
Volume 9, Issue 2, Pages 269-277

Publisher

SPRINGER
DOI: 10.1007/s12072-014-9605-x

Keywords

Non-alcoholic fatty liver disease; Discriminant score; Fibrosis

Ask authors/readers for more resources

Currently, non-alcoholic steatohepatitis (NASH) can only be diagnosed histopathologically. Our objective was to establish a new scoring system for the fibrotic stage of NASH. We enrolled 139 patients with histologically proven NASH and divided them into two groups to construct (n = 90) and validate (n = 49) a fibrotic score for NASH (FSN). We used 17 variables and their natural logarithmic transformations in the multivariate analysis. To assess the accuracy of the FSN in determining NASH advanced fibrosis (stages 3-4), we compared various fibrotic scores for NASH. In the construct group, multivariate regression analysis ultimately obtained the following function: z = 1.022 x ln (type IV collagen 7S) (ng/mL) - 0.00680 x (platelet count) (x10(9)/L) + 1.925 x ln (AST) (IU/L) - 1.239 x ln (ALT) (IU/L) + 0.249. Median values of the FSN for stages 1, 2, 3 and 4 were 1.87, 2.14, 3.26 and 3.89, respectively. The multiple regression coefficient and coefficient of determination were 0.70 and 0.46, respectively. In the validation group, the median value was 2.00, 2.83, 3.08 and 4.37 in each stage. With regard to the utility of the FSN for predicting advanced fibrosis of NASH (stage a parts per thousand yen3), the area under the receiver operating characteristic curves (AUROC), 0.909 (95 % CI 0.847-0.970, p < 0.001), was higher than that for the other fibrotic scores (APRI, NAFLD fibrosis score, FIB-4 index, BARD score, NIKEI) in the construct group. This simple scoring system accurately predicts fibrotic stage and discriminates patients with advanced fibrosis of NASH.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Gastroenterology & Hepatology

Clinicopathological assessment of steatohepatitic hepatocellular carcinoma

Kenji Yamaoka, Satoshi Saitoh, Keiichi Kinowaki, Shunichiro Fujiyama, Yusuke Kawamura, Hitomi Sezaki, Tetsuya Hosaka, Norio Akuta, Masahiro Kobayashi, Fumitaka Suzuki, Yoshiyuki Suzuki, Yasuji Arase, Kenji Ikeda, Toshio Fukusato, Hiromitsu Kumada

Summary: This study aimed to compare the clinicopathological features of typical steatohepatitic HCC (SH-HCC) with other HCCs. The results showed significant differences between SH-HCC and other HCCs in terms of age, hepatitis B virus (HBV) infection, nonalcoholic steatohepatitis (NASH), diabetes, and hyperlipidemia. Tumor size and background steatosis were also significantly different between the two groups. The combined use of ultrasonography, computed tomography (CT), and magnetic resonance imaging (MRI) improved the diagnostic accuracy of SH-HCC. According to LI-RADS, 87% of SH-HCC cases were classified as malignant tumors.

CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY (2022)

Editorial Material Gastroenterology & Hepatology

Editorial: can experimental biomarkers be useful for predicting HCC occurrence after sustained viral response in clinical settings?

Tetsuya Hosaka

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)

Article Gastroenterology & Hepatology

Renal safety and biochemical changes for 2 years after switching to tenofovir alafenamide from long-term other nucleotide analog treatment in patients with chronic hepatitis B

Tetsuya Hosaka, Fumitaka Suzuki, Masahiro Kobayashi, Shunichirou Fujiyama, Yusuke Kawamura, Hitomi Sezaki, Norio Akuta, Yoshiyuki Suzuki, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Mariko Kobayashi, Hiromitsu Kumada

Summary: This study found that switching from TDF or ADV to TAF resulted in favorable renal safety over 2 years. In the CKD stage 3a-4 subgroup, eGFR recovered within the first 12 weeks after TAF and then stabilized.

HEPATOLOGY RESEARCH (2022)

Article Oncology

The impact of lenvatinib on tumor blood vessel shrinkage of hepatocellular carcinoma during treatment: an imaging-based analysis

Nozomu Muraishi, Yusuke Kawamura, Norio Akuta, Junichi Shindoh, Masaru Matsumura, Satoshi Okubo, Shunichiro Fujiyama, Tetsuya Hosaka, Satoshi Saitoh, Hitomi Sezaki, Fumitaka Suzuki, Yoshiyuki Suzuki, Kenji Ikeda, Yasuji Arase, Masaji Hashimoto, Ichiro Yasuda, Hiromitsu Kumada

Summary: In this study, the effect of lenvatinib on tumor blood vessel diameter in patients with hepatocellular carcinoma was investigated. It was found that lenvatinib can reduce the diameter of tumor blood vessels, which may be considered as a process of normalization. The decrease in tumor blood vessels in imaging analysis may be associated with improved prognosis, but further studies are still required.

ONCOLOGY (2023)

Article Oncology

Simple predictive markers and clinicopathological features of primary liver cancer following HCV clearance with direct-acting antivirals.

Norio Akuta, Hitomi Sezaki, Shunichiro Fujiyama, Yusuke Kawamura, Tetsuya Hosaka, Mariko Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Yoshiyuki Suzuki, Fumitaka Suzuki, Hiromitsu Kumada

Summary: This study found that a combination of simple markers can help non-specialized doctors evaluate the risk of PLC following HCV clearance with DAAs. However, regular imaging studies are still recommended for the early detection of PLC.

ONCOLOGY (2023)

Article Gastroenterology & Hepatology

Well-preserved liver function enhances the clinical impact of curative-intent subsequent treatment during lenvatinib treatment for unresectable hepatocellular carcinoma

Yusuke Kawamura, Norio Akuta, Junichi Shindoh, Masaru Matsumura, Satoshi Okubo, Licht Tominaga, Shunichiro Fujiyama, Tetsuya Hosaka, Satoshi Saitoh, Hitomi Sezaki, Fumitaka Suzuki, Yoshiyuki Suzuki, Kenji Ikeda, Yasuji Arase, Masaji Hashimoto, Takuyo Kozuka, Hiromitsu Kumada

Summary: This study showed that curative-intent subsequent treatment is more beneficial for HCC patients with better liver function (mALBI grade 1 and 2a) and intrahepatic target nodules who have received lenvatinib treatment.

CLINICAL JOURNAL OF GASTROENTEROLOGY (2023)

Article Gastroenterology & Hepatology

Treatment efficacy of diet and exercise program for fatty liver and pretreatment predictors

Norio Akuta, Yusuke Kawamura, Shunichiro Fujiyama, Kenichi Nakamichi, Eiji Saegusa, Hidetoshi Ogura, Masaki Kato, Etsuko Doi, Naoko Inoue, Hitomi Sezaki, Tetsuya Hosaka, Mariko Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Yoshiyuki Suzuki, Hiromitsu Kumada, Fumitaka Suzuki

Summary: This retrospective cohort study evaluated the treatment efficacy and predictive factors of a combined diet and exercise program for fatty liver. The program improved liver function tests and body weight, and the etiology of non-NAFLD, presence of diabetes mellitus, and large waist circumference were identified as independent predictors of decreased hemoglobin A1c levels.

HEPATOLOGY RESEARCH (2023)

Article Oncology

Efficacy of the Combination of Systemic Sequential Therapy and Locoregional Therapy in the Long-Term Survival of Patients with BCLC Stage C Hepatocellular Carcinoma

Yusuke Kawamura, Norio Akuta, Junichi Shindoh, Masaru Matsumura, Satoshi Okubo, Licht Tominaga, Shunichiro Fujiyama, Tetsuya Hosaka, Satoshi Saitoh, Hitomi Sezaki, Fumitaka Suzuki, Yoshiyuki Suzuki, Kenji Ikeda, Yasuji Arase, Masaji Hashimoto, Takuyo Kozuka, Hiromitsu Kumada

Summary: This study analyzed the data of 64 BCLC stage C patients with intrahepatic target nodules who received systemic therapy. The results showed that the combined use of multiple treatment procedures improved the overall survival of patients with hepatocellular carcinoma.

CANCERS (2023)

Article Oncology

Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Early Progressive Disease following Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma

Yusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, Masaru Matsumura, Satoshi Okubo, Nozomu Muraishi, Shunichiro Fujiyama, Tetsuya Hosaka, Satoshi Saitoh, Hitomi Sezaki, Norio Akuta, Fumitaka Suzuki, Yoshiyuki Suzuki, Kenji Ikeda, Yasuji Arase, Masaji Hashimoto, Hiromitsu Kumada

Summary: The utility of F-18-fluorodeoxyglucose positron emission tomography/computed tomography (F-18-FDG-PET/CT) as a predictor of early progressive disease (e-PD) in hepatocellular carcinoma (HCC) patients treated with atezolizumab plus bevacizumab (Atezo/Bev) was investigated in this study. The results showed that a tumor-to-normal liver ratio (TLR) >= 2, indicating higher oncological aggressiveness, was associated with lower objective response rates, higher e-PD rates, and worse early progression-free survival (e-PFS). Pretreatment F-18-FDG-PET/CT may be a useful new predictor of e-PD and may enable early decision-making based on early treatment changes following Atezo/Bev treatment of HCC.

ONCOLOGY (2022)

Article Gastroenterology & Hepatology

Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5-year follow-up study

Norio Akuta, Yusuke Kawamura, Shunichiro Fujiyama, Satoshi Saito, Nozomu Muraishi, Hitomi Sezaki, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Yasuji Arase, Kenji Ikeda, Fumitaka Suzuki, Yoshiyuki Suzuki, Hiromitsu Kumada

Summary: This study investigated the impact of sodium-glucose cotransporter 2 inhibitor (SGLT2i) on nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes mellitus (T2DM) after 5 years of treatment. The results showed that, after 5 years, 50% of patients had histological improvement, 17% had no change, and 33% had worsening. Insulin resistance and serum ferritin levels also significantly decreased at 5 years. In addition, patients who added another treatment after long-term use of SGLT2i showed minimal worsening. This study provides important insights for understanding the long-term effects of SGLT2i in treating NAFLD with T2DM.

HEPATOLOGY COMMUNICATIONS (2022)

Article Gastroenterology & Hepatology

Ultrasensitive Assay for Hepatitis B Core-Related Antigen Predicts Hepatocellular Carcinoma Incidences During Entecavir

Tetsuya Hosaka, Fumitaka Suzuki, Mariko Kobayashi, Shunichiro Fujiyama, Yusuke Kawamura, Hitomi Sezaki, Norio Akuta, Masahiro Kobayashi, Yoshiyuki Suzuki, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada

Summary: The study found that measuring HBcrAg using an ultrasensitive assay has a better potential for predicting the development of hepatocellular carcinoma in patients with chronic hepatitis B undergoing antiviral treatment.

HEPATOLOGY COMMUNICATIONS (2022)

No Data Available